The management of patients with grade 2 IDH-mutant astrocytomas (non-1p/19q codeleted) is evolving as emerging data on IDH-targeted therapies refine risk assessment and challenge traditional treatment paradigms. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).